What is AxoGen?
Founded in 2002, AxoGen is dedicated to developing and producing advanced surgical solutions aimed at addressing peripheral nerve injuries. The company's comprehensive product line includes the Avance Nerve Graft for bridging severed nerves, the AxoGuard Nerve Connector for tensionless nerve repair, and the AxoGuard Nerve Protector for safeguarding injured peripheral nerves. Complementing these offerings are diagnostic tools such as the AcroVal neurosensory testing system and the AxoTouch discriminator. AxoGen's solutions are distributed to healthcare providers, including hospitals, surgery centers, and military medical facilities, across North America, Europe, and other international markets, supporting surgeons and patients in critical nerve repair procedures.
How much funding has AxoGen raised?
AxoGen has raised a total of $99.3M across 8 funding rounds:
Series B
$7.8M
Series C
$12.1M
Debt
$2.6M
Debt
$3.7M
Debt
$3M
Stock Offering
$18M
Share Placement
$17.1M
Debt
$35M
Series B (2006): $7.8M with participation from Springboard Capital
Series C (2007): $12.1M led by Springboard Capital II, Accuitive Medical Ventures, Cardinal Partners, and DeNovo Ventures
Debt (2009): $2.6M, investors not publicly disclosed
Debt (2011): $3.7M, investors not publicly disclosed
Debt (2011): $3M, investors not publicly disclosed
Stock Issuance/Offering (2013): $18M, investors not publicly disclosed
Share Placement (2015): $17.1M led by Essex Woodlands
Debt (2020): $35M supported by Oberland Capital Management LLC
Key Investors in AxoGen
Accuitive Medical Ventures
Accuitive Medical Ventures is a venture capital firm specializing in revolutionary medical device technology investment opportunities. They focus on venture financing for companies with outstanding technology and teams, often partnering with The Innovation Factory.
Cardinal Partners
Cardinal Partners is a venture capital partnership exclusively focused on healthcare investing since 1996, specializing in early-stage financing rounds as a lead investor for growth companies.
Essex Woodlands
EW Healthcare Partners is a healthcare growth equity firm that invests in companies across the US and Europe, focusing on pharmaceuticals, MedTech, and tech-enabled services to drive positive change and achieve high returns.
What's next for AxoGen?
The recent major strategic investment positions AxoGen for accelerated growth and further innovation in the peripheral nerve repair market. This capital infusion is expected to bolster the company's research and development efforts, potentially leading to new product introductions or enhancements to its existing portfolio. Furthermore, the financing may support an expansion of AxoGen's distribution network, enabling broader access to its surgical solutions in existing and new geographical regions. The company's focus on addressing a critical unmet need in medical care suggests a trajectory aimed at solidifying its leadership in the MedTech industry through strategic partnerships and market penetration.
See full AxoGen company page
